RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO™ beyond lung cancer RARITAN, N.J., Feb. 18, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and...

Read More